Aurinia Pharmaceuticals (AUPH) Receivables - Net (2016 - 2026)
Aurinia Pharmaceuticals' (AUPH) quarterly Receivables - Net came in at $49.2 million in Q1 2026, up 21.87% YoY from $40.4 million in Q1 2025, and up 18.63% on a QoQ basis from $41.5 million in Q4 2025.
Aurinia Pharmaceuticals (AUPH) Receivables - Net (2016 - 2026) Analysis & Trends
Aurinia Pharmaceuticals (AUPH) has 10 years of Receivables - Net data on file, last reported at $49.2 million in Q1 2026.
- Quarterly Receivables - Net rose 21.87% year-over-year to $49.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.2 million (up 21.87% YoY) and the FY2025 annual result came in at $41.5 million, up 13.44% from the prior year.
- Receivables - Net climbed to $49.2 million in Q1 2026, from $41.5 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $49.2 million in Q1 2026 to a low of $13.5 million in Q4 2022.
- A 5-year average of $30.8 million and a median of $30.7 million in 2025 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2022 — Receivables - Net surged 1618.7% — and 2025, when it dropped 15.77%.
- Tracing AUPH's Receivables - Net over 5 years: stood at $13.5 million in 2022, then soared by 78.44% to $24.1 million in 2023, then surged by 51.7% to $36.5 million in 2024, then gained by 13.44% to $41.5 million in 2025, then grew by 18.63% to $49.2 million in 2026.
- The last three Receivables - Net figures came in at $49.2 million (Q1 2026), $41.5 million (Q4 2025), and $30.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Aurinia Pharmaceuticals | 2.06 Bn | 1.61 Bn | 76.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.14 Mn |
| Jun 30, 2026 | 41.14 Mn |
| Mar 31, 2026 | 49.18 Mn |
| Mar 31, 2026 | 49.18 Mn |
| Dec 31, 2025 | 41.45 Mn |
| Dec 31, 2025 | 41.45 Mn |
| Sep 30, 2025 | 30.73 Mn |
| Sep 30, 2025 | 30.73 Mn |
| Jun 30, 2025 | 40.09 Mn |
| Jun 30, 2025 | 40.09 Mn |
| Mar 31, 2025 | 40.35 Mn |
| Mar 31, 2025 | 40.35 Mn |
| Dec 31, 2024 | 36.54 Mn |
| Dec 31, 2024 | 36.54 Mn |
| Sep 30, 2024 | 36.48 Mn |
| Sep 30, 2024 | 36.48 Mn |
| Jun 30, 2024 | 25.52 Mn |
| Jun 30, 2024 | 25.52 Mn |
| Mar 31, 2024 | 28.91 Mn |
| Mar 31, 2024 | 28.91 Mn |